Physician profile
Matthew Cooper
NPI 1740204965
$98,389.17
in general payments reported to CMS, 2019-2025
13 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,255 · 2021: $351 · 2022: $4,271 · 2023: $13K · 2024: $21K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $21K · Travel and Lodging: $6,293 · Honoraria: $6,050 · Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,438.50 |
| Consulting Fee | $20,930.00 |
| Travel and Lodging | $6,293.04 |
| Honoraria | $6,050.00 |
| Food and Beverage | $799.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65,656.23 | 2021-2025 | |
| Veloxis Pharmaceuticals, INC. | $9,813.74 | 2022-2023 | Envarsus |
| Biogen, INC. | $7,930.00 | 2025 | |
| Genzyme Corporation | $4,802.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $4,495.00 | 2025 | |
| Merck Sharp & Dohme LLC | $2,714.75 | 2023-2024 | |
| National Marrow Donor Program | $2,400.00 | 2022-2025 | |
| Saol Therapeutics INC. | $303.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Abbvie INC. | $124.12 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.